ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.
Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.
Search Tips:
- Use the keyword search to search by keyword or author's name.
- Filter your search results by selecting the checkboxes that apply.
- Click on "Clear" to clear the form and start a new search. .
Search results will display below the form.
Adolescent and Young Adult Use of Tobacco and Nicotine Products: Associations with Respiratory Symptoms
Session Title
TP68 - TP068 TOBACCO PRODUCT EXPOSURES IN PEDIATRIC SUBJECTS
Abstract
A3199 - Adolescent and Young Adult Use of Tobacco and Nicotine Products: Associations with Respiratory Symptoms
Author Block: A. P. Tackett1, T. Islam1, M. E. Rebuli2, S. N. Cwalina1, S. L. Smiley1, S. P. Eckel1, A. M. Leventhal1, J. L. Barrington-Trimis1, R. McConnell1; 1Preventive Medicine, University of Southern California, Los Angeles, CA, United States, 2Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Rationale: In the United States (US), the number of adolescents and young adults (AYAs) who use electronic cigarettes (e-cigarettes) continues to increase, with estimates at 5.4 million new users in 2019. E-cigarettes are the most commonly used tobacco product among AYAs, but it is difficult disentangle the risk of asthma and related respiratory symptoms associated with e-cigarette use due to the frequency of co-use with combustible cigarettes and cannabis products. This study examined associations between e-cigarette, cigarette, and cannabis use and self-reported 1) asthma diagnosis, 2) shortness of breath (SOB), and 3) wheeze. Methods: A sample of US AYAs (N = 2931; Mean age=18.9 [SD=1.6]; 80% female; 75% white) provided cross-sectional, self-report data via a web-based survey from August 6 to 31, 2020. Questionnaires assessed AYA demographics (age, sex at birth, race/ethnicity), self-reported asthma diagnosis, frequency of respiratory symptoms over past 30 days (SOB, wheeze) and co-product use (e-cigarette, cigarette, and cannabis). Multivariable logistic regressions were used to evaluate the associations between past 30-day e-cigarette, cigarette, and cannabis use and asthma diagnosis, wheeze, and SOB. Results: The prevalence of asthma, wheeze, and SOB among AYAs was 24%, 13%, and 20%, respectively. Among past 30-day current e-cigarette users (n=1414), 15% reported current use of cigarettes and 37% reported cannabis use. After controlling for age, sex at birth, and race/ethnicity, past 30-day e-cigarette use was associated increased odds of self-reported asthma (Odds ratio (OR): 1.4, 95% CI:1.1 - 1.7), wheeze (OR:3.1, 95% CI:2.3 - 4.2), and SOB (OR:2.9, 95%CI:2.3 - 3.6), compared to never e-cigarette users. After controlling for past 30-day cigarette and cannabis use, past 30-day e-cigarette use was no longer associated with asthma (1.11, 95% CI:0.87-1.41), but still associated with increased wheeze (OR: 2.3, 95%CI: 1.6-3.0) and SOB (OR: 2.1, 95%CI:1.6-2.8). Conclusion: In this cross-sectional convenience sample of AYAs from the US, e-cigarette use was associated with increased risk of wheeze and SOB, after controlling for cigarette and cannabis use. Longitudinal studies are needed to further determine the long-term health effects of e-cigarette use and whether concurrent use with cigarettes or cannabis will increase the burden of respiratory disease.
Author Block: A. P. Tackett1, T. Islam1, M. E. Rebuli2, S. N. Cwalina1, S. L. Smiley1, S. P. Eckel1, A. M. Leventhal1, J. L. Barrington-Trimis1, R. McConnell1; 1Preventive Medicine, University of Southern California, Los Angeles, CA, United States, 2Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Rationale: In the United States (US), the number of adolescents and young adults (AYAs) who use electronic cigarettes (e-cigarettes) continues to increase, with estimates at 5.4 million new users in 2019. E-cigarettes are the most commonly used tobacco product among AYAs, but it is difficult disentangle the risk of asthma and related respiratory symptoms associated with e-cigarette use due to the frequency of co-use with combustible cigarettes and cannabis products. This study examined associations between e-cigarette, cigarette, and cannabis use and self-reported 1) asthma diagnosis, 2) shortness of breath (SOB), and 3) wheeze. Methods: A sample of US AYAs (N = 2931; Mean age=18.9 [SD=1.6]; 80% female; 75% white) provided cross-sectional, self-report data via a web-based survey from August 6 to 31, 2020. Questionnaires assessed AYA demographics (age, sex at birth, race/ethnicity), self-reported asthma diagnosis, frequency of respiratory symptoms over past 30 days (SOB, wheeze) and co-product use (e-cigarette, cigarette, and cannabis). Multivariable logistic regressions were used to evaluate the associations between past 30-day e-cigarette, cigarette, and cannabis use and asthma diagnosis, wheeze, and SOB. Results: The prevalence of asthma, wheeze, and SOB among AYAs was 24%, 13%, and 20%, respectively. Among past 30-day current e-cigarette users (n=1414), 15% reported current use of cigarettes and 37% reported cannabis use. After controlling for age, sex at birth, and race/ethnicity, past 30-day e-cigarette use was associated increased odds of self-reported asthma (Odds ratio (OR): 1.4, 95% CI:1.1 - 1.7), wheeze (OR:3.1, 95% CI:2.3 - 4.2), and SOB (OR:2.9, 95%CI:2.3 - 3.6), compared to never e-cigarette users. After controlling for past 30-day cigarette and cannabis use, past 30-day e-cigarette use was no longer associated with asthma (1.11, 95% CI:0.87-1.41), but still associated with increased wheeze (OR: 2.3, 95%CI: 1.6-3.0) and SOB (OR: 2.1, 95%CI:1.6-2.8). Conclusion: In this cross-sectional convenience sample of AYAs from the US, e-cigarette use was associated with increased risk of wheeze and SOB, after controlling for cigarette and cannabis use. Longitudinal studies are needed to further determine the long-term health effects of e-cigarette use and whether concurrent use with cigarettes or cannabis will increase the burden of respiratory disease.
